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ORIGINAL RESEARCH ARTICLE
A review of echocardiograms in hypertensive patients greater than 60 years
in a community based family medicine program
Shideh Doroudi, Michael D. DeLisi and Vincent A. DeBari
New York Medical College, School of Medicine/St. Joseph’s Family Medicine Department, Paterson, NJ, USA
ABSTRACT
Background: Heart disease as a result of Hypertension is known to occur. Anatomical and
functional changes of the heart can easily be detected by echocardiography, which is a safe and
readily available study.
Objectives: The aims of this studywere to evaluate the prevalence of common echocardiographic
changes in chronic hypertensive patients and to compare these changes in male and female
populations.
Design/methods: The study was a community-based cross-sectional study, on 227 hyper-
tensive patients, 60 years and older, seen in St. Joseph’s Family Medicine at Clifton, with
integrated clinical and echocardiographic data.
Results: Study population consisted of 227 hypertensive patients, over the age of 60 years
who had echocardiography done. Overall 92.5% of the echocardiograms had abnormal
findings including but not limited to TR, Diastolic dysfunction, MR, and LVH. There was
significant difference between the rate of MR in male and female population.
Conclusion: A variety of echocardiographic abnormalities can be found in hypertensive
patients. Drug selection in hypertension should be driven by the underlying cardiac pathol-
ogy. Certain drugs have more effectiveness for diastolic dysfunction, LVH, systolic dysfunction
and pulmonary hypertension and are superior choices when these conditions are present.
Echocardiogram is a non-invasive and easily available tool in order to help us to select the
best treatment strategy to optimize hypertensive control in the challenging group of elderly
patients. The results of our study should influence us to liberally use echocardiography in
these patients to guide treatment decision and drug selection.
Abbreviations: LVH: left ventricular hypertrophy; MR: mitral valve regurgitation; TR: tricus-
pidvalve regurgitation; LVD: left ventricular dilation; LVEF: left ventricular ejection fraction
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Hypertension is a chronic medical condition seen in a
considerable proportion of patients in a primary care
setting. Heart disease as a result of Hypertension is
known to occur. Left Ventricular Hypertrophy (LVH)
in hypertensive Patients is a marker of the burden on
the heart of multiple modifiable and non-modifiable risk
factors [1]. Prospective studies have consistently shown
that effective long-term blood pressure (BP) lowering
may prevent or reduce LVH [2]. Hypertension is also a
substantial risk factor for heart failure, particularly via left
ventricular diastolic dysfunction, characterized by thick-
ening of the left ventricular wall. Anatomical changes and
functional changes of the heart can easily be detected and
imaged by echocardiography, which is a real-time,
quick, safe, and easily available imaging study. Many of
the studies reviewed, involved large proportions
of Caucasian ethnicities which is not representative of
many of the largemetropolitan and urban centers in large
cities throughout the world. With migration of different
ethnicities to various parts of the world, health care
providers will be better equipped to understand their
patient population’s specific needs if they are provided
with research and data that contains variable stratifica-
tions of varied ethnicity, ages, and comorbidities. While
there have been a number of studies published within
the past five years examining the relationship between
hypertension, echocardiographic changes, and the vari-
ables associated, a significant proportion of the data was
obtained frommany years prior. The patient population
seen at Clifton Family Practice offers a variance in terms
of ethnicity, age, BMI, treatment regimen, stage of
hypertension at initial presentation, compliance, and
comorbidities. The aims of this study were to evaluate
the prevalence of common echocardiographic changes
in chronic hypertensive patients in a community based
familymedicine program and to compare these changes
between male and female population.
2. Design/methods
2.1. Study design
A clinic-based cross-sectional study.
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2.2. Data collection
A registry report was run on hypertensive patients.
The family medicine’s electronic database was used.
This was done in December 2013. We used electronic
data base.
2.3. Study population
Our target population was patients 60 years and
older with diagnosis of hypertension in their pro-
blem list. We chose 60 years to increase the num-
ber of the study population and improve the power
of the study. Hypertension was defined using
GNC7 guideline. We found 548 patients, from
whom, 227 had echocardiogram done in the last
8 years. We included the most recent echocardio-
grams available. None of the echocardiograms were
interpreted by study investigators. It comprised 143
female and 84 male patients, seen in Clifton Family
Practice, with integrated clinical and transthoracic
echocardiographic data. All patients seen by family
physicians. So in summary, all hypertensive
patients who were 60 years and older, and had an
echocardiogram in their medical record, were
included in the study and all others excluded.
Data was analyzed for age, gender, date of echocar-
diogram, reason for echocardiogram and common
echocardiographic findings including: Left ventri-
cular ejection fraction (LVEF), Left ventricular
hypertrophy (LVH), Left atrium enlargement,
Right atrium enlargement, right ventricular enlar-
gement, valvular abnormalities, pulmonary hyper-
tension and pericardial effusion.
2.4. Definitions and classifications
LVEF of 50% and higher considered normal. Pulmonary
hypertension was defined as pulmonary artery pressure
(systolic), above 25 [3]. Valvular abnormalities classified
as stenosis or insufficiency meaning that other findings
including thickened, sclerotic and calcified valves with-
out evidence of stenosis or insufficiency classified as
normal.
2.5. Statistical analysis
Interval data were tested for normality using the
D’Agostino-Pearson omnibus normality test. Non-
normally distributed interval data (age) are presented
as medians and interquartile ranges (IQR). Analysis
of categorical data, with gender as the exposure
(female v. male) was carried out with Fisher’s exact
test. Because of the retrospective nature of the study,
the odds ratio (OR) is used as a measure of effect size
with the 95% confidence interval (95 CI) as a measure
of dispersion.
The value of α was 0.05, thus p < 0.05 (two-sided)
was required for statistical significance. Analyses were
conducted with Prism® v. 6 software (GraphPadCorp. San Diego CA, USA).
3. Results
Study comprised 143 female (63%) and 84 male
(37%) hypertensive patients 60 years and older with
median age of 66 with interquartile range between 62
and 73 years, who had echocardiogram done during
the last 8 years (average of 2.4 years). 60% of our
study population were between 60 and 69 years old
(Table 1).
Reasons for requesting echocardiogram includ-
ing hypertension, cardiac murmur, heart failure,
valve disease, chest pain, coronary artery disease,
palpitation, Shortness of breath, CVA and arrhyth-
mia but all patients were hypertensive. Overall
92.5% of the echocardiograms had abnormal find-
ings. 57% had tricuspid regurgitation including
mild (48%), moderate (7.5%), and severe (0.8%)
(Figure 1).
49% of the patients had diastolic dysfunction with
47.6% Grade 1 and 1.4% Grade 2 diastolic
dysfunction.
42% of the patients hadmitral regurgitation, including
mild (34%), mild to moderate (1.3%), moderate (5%),
moderate to severe (1.3%), and severe (0.4%) (Figure 2).
57% of the patients had normal left ventricular
dimensions, 37% had LVH, 5% had left ventricular
dilation and 1% had combination of left ventricular
dilation and LVH (Figure 3).
32% of the patients had left atrial enlargement of
those 29% had mild and only 3% had moderate and
severe left atrial enlargement. 5% of the population
had right atrial dilation. 93% of the patients had
normal and 7% had impaired left ventricular ejec-
tion fraction. (Less than 50%), including LVEF of
35–50% (3.5%) and less than 35% (3.5%)
(Figure 4).
2.2%) of the patients had right ventricular dila-
tion. Aortic valve abnormalities including 12% AI,
3.5%) AS. Only one patient was found to have a
combination of AS and AI. 7% was found to have
pulmonary valve insufficiency. 15% of the patients
had pulmonary artery hypertension. In compari-
sons between male and female gender, there was
one significant difference in the above mentioned
echocardiographic changes was mitral regurgita-
tion, with 36.4% in female and 52% in male popu-
Table 1. Age demographic of study population.
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lation [OR: 0.52, CI 95% (0.30–0.90)], and p-value
of 0.026.
We have reviewed 16 different studies in our lit-
erature review. As a result we found Left ventricular
hypertrophy to be a common echocardiographic
finding in hypertensive patients [1,4–7] and found
that Ace-Inhibitors like enalaprilat demonstrated
promising myocardial remodeling effects in
experimental models of hypertensive heart disease
[8]. Another finding in our literature review was the
development of left ventricular diastolic dysfunction
which may precede hypertrophy and may be one of
the earliest changes associated with hypertensive
heart disease. This finding can be assessed with echo-
cardiogram and amlodipine, atenolol, as well as
Lisinopril were found to improve this co-morbidity























Figure 1. Percent of subjects with varying degrees of tricuspid valve insufficiency.
Note that the graph is broken at 1% to show the 0.8 percent of subjects with severe tricuspid valve insufficiency.























Figure 2. Percent of subjects with varying degrees of mitral valve insufficiency.
Note that the graph is broken at 1% to show the 0.4 percent of subjects with severe mitral valve insufficiency.
30 S. DOROUDI ET AL.
as discussed further in our discussion [9–13].
Another study revealed that lowering blood pressure
improves diastolic function irrespective of the type of
antihypertensive agent used [14]. We also studied
other echocardiograms findings including left atrial
enlargement and aortic valve stenosis in the existing
literature and compared with those in our
population.























Figure 3. Percent of subjects with varying degrees of left ventricular hypertrophy/dilation.
Note that the graph is broken at 1% to show the 0.4 percent of subjects with moderate and severe left ventricular hypertrophy.




















Figure 4. Percent of subjects with varying degrees of left ventricular ejection fraction.
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4. Discussion
The present study assessed the prevalence of different
echocardiographic changes in a cohort of hyperten-
sive individuals 60 years and older who presented to a
community based family medicine program. Reasons
for echocardiogram in this population were different
but they all had hypertension as one of the diagnoses
in their problem list. Echocardiography is a mode of
investigation that is noninvasive and assesses anato-
mical structure and function of the heart via a multi-
tude of parameters. Left ventricular Hypertrophy is a
preclinical organ damage frequently observed in
human hypertension, reflecting the impact of chronic
pressure overload on the heart [5]. In our literature
review, a study done in Sweden showed sixteen per-
cent of the healthy population versus 45% of the
hypertensive patients demonstrated the presence of
LVH [4]. In another study done in Italy, the preva-
lence of LVH in a total of 2249 hypertensive subjects
with mean age of 62 was reported to be 65% [1].
Tovillas-Moran et al. reported the prevalence of
LV hypertrophy to be 63.8% [7]. A Chinese study
reported LVH to be a major complication of
Hypertension with prevalence of 42.7% [6]. The
above mentioned studies showed higher rates of
LVH than what we found in our study (38%), but
we can conclude that LVH is a common echocardio-
graphic finding in hypertensive patients.
An article review done by Ferreira Fiho et al., con-
cluded that anti-hypertensive drugs induced various
degrees of hypertrophic regression for example Ace-
inhibitors demonstrated promising myocardial remo-
deling effects in experimental models of hypertensive
heart disease. Enalaprilat in particular increased the
regression of hypertrophy in the left ventricular, but
not in the diaphragm or the gastrocnemius muscles [8].
The development of left ventricular diastolic dysfunc-
tion may precede hypertrophy and may be one of the
earliest changes associated with hypertensive heart dis-
ease. Notably, diastolic dysfunction may not be accom-
panied by symptoms and is usually a chance finding
during aDoppler echocardiographic examination.
Since left ventricular diastolic dysfunction as
assessed by Doppler echocardiography can predict
mortality in middle-aged and elderly adults, this
tool has acquired an important clinical position
[10]. Prevalence of Left ventricular diastolic dysfunc-
tion in a random sample of a general population was
estimated to be as high as 27.3% which is lower than
the rate we found in our study (48%) [9]. The popu-
lation in our study was hypertensive with a higher
mean age and many with other medical co morbid-
ities like diabetes, hyperlipidemia, and coronary
artery disease, etc.
Setaro et al. reported verapamil to improve exer-
cise capacity and diastolic function [11].
A long-term study, the EL VERA trial proves that
amlodipine and lisinopril reduce left ventricular mass
and improve diastolic function to a similar extent in
elderly newly diagnosed hypertensive patients [12]. In
a prospective, randomized study of 1006 patients with
hypertension treated fo a year, Tapp et al. found that
patients receiving treatment with an amlodipine-
based regimen had better diastolic function than
patients treated with the atenolol-based regimen.
Treatment-related differences in diastolic function
were independent of BP reduction and other factors
that are known to affect diastolic function [13].
In the study done by Muller-Brunotte et al.,
Irbesartan and Atenolol improved diastolic dys-
function [15] and in Solomon SD’s study,
Valsartan was no different from other hypertension
medication (matched placebo) in improving diasto-
lic function [14].
Left atrial size has been shown to be a predictor,
not only of atrial fibrillation, stroke, and congestive
heart failure, but also of overall cardiovascular risk.
Cuspidi et al. [16] found left atrial enlargement to be
a frequent finding in hypertensive patients. This
abnormality was found to be strongly related to left
ventricular hypertrophy and to diastolic dysfunction.
For these reasons, in the European Society of
Cardiology’s latest guidelines for the management of
arterial hypertension the measurement of left atrial
size is strongly recommended [10]. We found 32% of
our sample population to have Left Atrial
Enlargement. The prevalence of critical Aortic valve
stenosis in 552 persons of a randomly selected men
and women in the age group of 55–86 was found to
be 2.2% [17] which was higher than what we found in
our review (0.9%).
Overall, Given that hypertension is usually
detected and controlled in Primary Health Care, this
implies that Primary Health Care patients could be
more representative of the general hypertensive
population [7].
5. Conclusion
A variety of echocardiographic abnormalities can be
found in hypertensive patients, rates vary in different
studies. Review of the literature concludes that drug
selection in hypertension should be driven by the under-
lying cardiac pathology. It also suggests that certain drugs
have more effectiveness for diastolic dysfunction, LVH,
systolic dysfunction and pulmonary hypertension and
are superior choices when these conditions are present.
Echocardiogram is a non-invasive, easily available and
valuable tool in elderly hypertensive patients in order to
identify common underlying cardiac abnormalities
which should help us to select the best treatment strategy
to optimize hypertensive control in this challenging and
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varied group of patients. The high prevalence of Diastolic
dysfunction and LVH in elderly hypertensive patients,
found in our study, should influence us to liberally use
echocardiography in these patients to guide treatment
decision and drug selection.
5.1. Limitations
At the time of study complete demographic data was
not available. Also other co-morbid conditions might
have affected the echocardiogram results.
5.2. Strengths
This study is one of the largest reviews in the literature.
We reviewed a true real world and diverse population in
our study.
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